Csl Limited (CSLLY) 33.5000 $CSLLY
Guillain-Barre Syndrome Global Clinical Trials Review, H1, 2014: Espy the Commercial Landscape of the Major Universities / Institutes / Hospitals & Companies
M2 - Fri Aug 15, 4:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2fqtrx/guillainbarre) has announced the addition of the "Guillain-Barre Syndrome Global Clinical Trials Review, H1, 2014" report to their offering. "Guillain-Barre Syndrome Global Clinical Trials Review, H1, 2014" provides data on the Guillain-Barre Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Guillain-Barre Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Guillain-Barre Syndrome. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Harvard Pilgrim Health Care, Inc. - GlaxoSmithKline plc - CSL Limited Clinical Trial Overview of Top Institutes / Government - Erasmus MC - FDA Office of Orphan Products Development - Chhatrapati Shahuji Maharaj Medical University - Mansoura University - University Medical Centre Ljubljana - University of Versailles - University of Cologne - NHS Greater Glasgow and Clyde - National Taiwan University Hospital For more information visit http://www.researchandmarkets.com/research/2f...llainbarre
Global Blood Plasma Market Report: 2014 Edition
M2 - Fri Jul 11, 8:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v86kh7/global_blood) has announced the addition of the "Global Blood Plasma Market Report: 2014 Edition" report to their offering. With the swift changes and advancement in biomedical/healthcare technology, the healthcare/pharmaceutical/therapeutic industry is becoming ever more competitive. Also, increasing incidences of health related issues owing to changing lifestyles is augmenting the blood plasma industry's growth. In order to address the rising medical needs related to blood disorders such as autoimmune diseases and liver function impairment among others, market players are coming up with novel and improved treatment options like IVIG, albumin, clotting factors etc. which are derived from human blood plasma. The blood plasma industry is highly regulated to ensure the safety of collected plasma and protect donors. The market is characterized by fast pace developments in the clinical technology and testing methodology. The report, Global Blood Plasma Market presents different facets of the global blood plasma market with a focus on sub-markets like IVIG, albumin and hemophilia market. Moreover, market dynamics like the key trends, industry developments, growth drivers and challenges are analyzed in detail. Furthermore, the competitive landscape of the industry is presented. The market remains highly concentrated and is dominated by a handful of players including CSL, Grifols, Baxter and Octapharma. The profiles of these leading players are also included in the report along with their key financials and strategies for growth. Key Topics Covered: 1. Overview 2. Blood Plasma Market Analysis 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Mentioned - Baxter International Inc. - CSL Limited - Grifols - Octapharma AG For more information visit http://www.researchandmarkets.com/research/v8...obal_blood
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials Review, H1, 2014
M2 - Tue Jul 08, 9:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n6tm85/chronic) has announced the addition of the "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Clinical Trials Review, H1, 2014" report to their offering. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Clinical Trials Review, H1, 2014" provides data on the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - CSL Limited - LFB S.A. - Biogen Idec Inc. - Takeda Pharmaceutical Company Limited - Octapharma AG - Novartis AG - Kedrion S.p.A. - Grifols, S.A. - Grifols Deutschland Gmbh - GeNeuro SA - National Center for Research Resources - Aarhus University - Erasmus MC - State University of New York at Buffalo - Stony Brook University - University of Cologne - Northwestern University - Centre Hospitalier Universitaire de Saint Etienne - Oregon Health and Science University - Rigshospitalet For more information visit http://www.researchandmarkets.com/research/n6tm85/chronic
Guillain-Barre Syndrome Global Clinical Trials Review, H1, 2014: Espy the Commercial Landscape of the Major Universities / Institutes / Hospitals & Companies
M2 - Fri Aug 15, 4:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2fqtrx/guillainbarre) has announced the addition of the "Guillain-Barre Syndrome Global Clinical Trials Review, H1, 2014" report to their offering. "Guillain-Barre Syndrome Global Clinical Trials Review, H1, 2014" provides data on the Guillain-Barre Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Guillain-Barre Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Guillain-Barre Syndrome. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Harvard Pilgrim Health Care, Inc. - GlaxoSmithKline plc - CSL Limited Clinical Trial Overview of Top Institutes / Government - Erasmus MC - FDA Office of Orphan Products Development - Chhatrapati Shahuji Maharaj Medical University - Mansoura University - University Medical Centre Ljubljana - University of Versailles - University of Cologne - NHS Greater Glasgow and Clyde - National Taiwan University Hospital For more information visit http://www.researchandmarkets.com/research/2f...llainbarre
Global Blood Plasma Market Report: 2014 Edition
M2 - Fri Jul 11, 8:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v86kh7/global_blood) has announced the addition of the "Global Blood Plasma Market Report: 2014 Edition" report to their offering. With the swift changes and advancement in biomedical/healthcare technology, the healthcare/pharmaceutical/therapeutic industry is becoming ever more competitive. Also, increasing incidences of health related issues owing to changing lifestyles is augmenting the blood plasma industry's growth. In order to address the rising medical needs related to blood disorders such as autoimmune diseases and liver function impairment among others, market players are coming up with novel and improved treatment options like IVIG, albumin, clotting factors etc. which are derived from human blood plasma. The blood plasma industry is highly regulated to ensure the safety of collected plasma and protect donors. The market is characterized by fast pace developments in the clinical technology and testing methodology. The report, Global Blood Plasma Market presents different facets of the global blood plasma market with a focus on sub-markets like IVIG, albumin and hemophilia market. Moreover, market dynamics like the key trends, industry developments, growth drivers and challenges are analyzed in detail. Furthermore, the competitive landscape of the industry is presented. The market remains highly concentrated and is dominated by a handful of players including CSL, Grifols, Baxter and Octapharma. The profiles of these leading players are also included in the report along with their key financials and strategies for growth. Key Topics Covered: 1. Overview 2. Blood Plasma Market Analysis 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Mentioned - Baxter International Inc. - CSL Limited - Grifols - Octapharma AG For more information visit http://www.researchandmarkets.com/research/v8...obal_blood
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials Review, H1, 2014
M2 - Tue Jul 08, 9:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n6tm85/chronic) has announced the addition of the "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Clinical Trials Review, H1, 2014" report to their offering. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Clinical Trials Review, H1, 2014" provides data on the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - CSL Limited - LFB S.A. - Biogen Idec Inc. - Takeda Pharmaceutical Company Limited - Octapharma AG - Novartis AG - Kedrion S.p.A. - Grifols, S.A. - Grifols Deutschland Gmbh - GeNeuro SA - National Center for Research Resources - Aarhus University - Erasmus MC - State University of New York at Buffalo - Stony Brook University - University of Cologne - Northwestern University - Centre Hospitalier Universitaire de Saint Etienne - Oregon Health and Science University - Rigshospitalet For more information visit http://www.researchandmarkets.com/research/n6tm85/chronic
